CLB — Core Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00
- $797.52m
- $932.87m
- $509.79m
- 90
- 34
- 55
- 61
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 94.3 | -97.1 | 20.2 | 19.7 | 37 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 16.7 | 140 | 12.4 | 12.7 | 11.6 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.71 | 5.94 | -20.6 | -25 | -28.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 89.5 | 57.9 | 36.6 | 25 | 24.8 |
Capital Expenditures | -22.3 | -11.9 | -13.5 | -10.2 | -10.6 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 16.6 | 19.7 | 3.32 | 6.36 | 3.93 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -5.68 | 7.85 | -10.2 | -3.86 | -6.65 |
Financing Cash Flow Items | 0.008 | -1.77 | -1.37 | -2.62 | -5.38 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -85.9 | -63 | -22.5 | -23.4 | -18.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.02 | 2.71 | 3.9 | -2.27 | -0.308 |